[go: up one dir, main page]

 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (1,632)

Search Parameters:
Keywords = human papillomavirus

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
10 pages, 775 KiB  
Article
Treatment with Epigallocatechin Gallate, Folic Acid, Vitamin B12, and Hyaluronic Acid Decreases HPV Positivity in Women Attending Regional Screening in Puglia
by Andrea Tinelli, Sarah Gustapane, Martina Licchelli, Anna Chiara Coluccia, Gaetano Panese, Sara Proietti and Riccardo Gambioli
Microorganisms 2024, 12(9), 1897; https://doi.org/10.3390/microorganisms12091897 - 14 Sep 2024
Viewed by 276
Abstract
Human Papillomavirus (HPV) infection represents a global health concern. HPV infects the mucosa, particularly in the uterine cervix, where it may establish a persistent infection, exposing women to a risk of developing cancer. The available treatments include surgery or topic solutions, while a [...] Read more.
Human Papillomavirus (HPV) infection represents a global health concern. HPV infects the mucosa, particularly in the uterine cervix, where it may establish a persistent infection, exposing women to a risk of developing cancer. The available treatments include surgery or topic solutions, while a systemic treatment is still unavailable. In recent years, natural molecules such as epigallocatechin gallate (EGCG), folic acid (FA), vitamin B12, and hyaluronic acid (HA) gained importance as innovative therapies for HPV. We enrolled 163 women with a positive HPV DNA test or previous history of HPV infections, and a PAP test indicating LSIL/AGUS/ASCUS cytology. The patients in the treatment group (n = 86) received an oral combination of EGCG 200 mg, FA 400 µg, vitamin B12 1 mg, and HA 50 mg (1 cps/day) for 3 months (T1), while the control group (n = 77) underwent standard clinical surveillance. Both groups repeated a PAP test and an HPV DNA test after 3 (T1) months, and another PAP test after 6 months (T2) as a follow up. The treatment group experienced a significant reduction in HPV positivity at T1 compared to the control group. Moreover, the treatment group exhibited an improvement in cervical lesions either at T1 (p < 0.0001) or T2 (p < 0.00001). Full article
(This article belongs to the Special Issue Human Papillomavirus Infections in Public Health and Pathology)
Show Figures

Figure 1

Figure 1
<p>The graphs represent a comparison of HPV positivity between the control and treatment groups at baseline (T0) and after treatment (T1). (<b>a</b>) At T0, both the control and treatment groups showed similar levels of HPV positivity. (<b>b</b>) After 3 months of treatment (T1), the treatment group showed a significant decrease in HPV positivity compared to the control group (** <span class="html-italic">p</span> &lt; 0.01).</p>
Full article ">Figure 2
<p>The graphs represent a comparison of cervical lesions in the control and treatment groups at baseline (T0), after 3 months (T1), and at 6 months (T2). At baseline (T0), both control and treatment groups showed similar cytology of cervical lesions (<b>a</b>). After 3 months of treatment (T1) and 6 months (T2) (<b>b</b>,<b>c</b>), the treatment group showed a significant improvement in cervical lesions (*** <span class="html-italic">p</span> &lt; 0.0001 and **** <span class="html-italic">p</span> &lt; 0.00001).</p>
Full article ">
14 pages, 783 KiB  
Review
Skin Lesions Caused by HPV—A Comprehensive Review
by Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog and Anca Huniadi
Biomedicines 2024, 12(9), 2098; https://doi.org/10.3390/biomedicines12092098 - 13 Sep 2024
Viewed by 357
Abstract
This narrative review provides a comprehensive analysis of skin lesions caused by human papillomavirus (HPV). Human papillomavirus is an infection involving a virus that is omnipresent and can range from benign wart lesions to malignant skin growths. This review includes an analysis of [...] Read more.
This narrative review provides a comprehensive analysis of skin lesions caused by human papillomavirus (HPV). Human papillomavirus is an infection involving a virus that is omnipresent and can range from benign wart lesions to malignant skin growths. This review includes an analysis of the skin manifestations caused by HPV, and the need for continued successful diagnostic techniques and treatment methods, given the increasing rates of infection among people worldwide. We reviewed all 135 studies related to pathophysiology involving skin, risk factors, and early detection methods like biopsy and molecular testing, from 2000 to 2023. The current treatments, including cryotherapy and laser therapy, are discussed, while the review emphasizes the role of HPV vaccination in preventing infection. Recommendations for the future would involve the improvement of public education and increased vaccine coverage, together with innovative therapies toward better management or control of skin diseases associated with the human papillomavirus (HPV). By advancing these recommendations, we will be in a better position to prevent and treat HPV skin conditions, thus improving the health condition of the general public across the world. Full article
(This article belongs to the Special Issue Current Perspectives on Human Papillomavirus (HPV))
Show Figures

Figure 1

Figure 1
<p>HPV infection mechanism.</p>
Full article ">
9 pages, 945 KiB  
Communication
The Impact of Human Papillomavirus Infections on Recurrent Pregnancy Loss: A Review of the Literature
by Dimitra Dedousi, Anastasios Potiris, Athanasios Zikopoulos, Theodoros Karampitsakos, Spyridon Topis, Charikleia Skentou, Angeliki Gerede, Panagiotis Christopoulos, Athanasios Zachariou, Ekaterini Domali, Peter Drakakis and Sofoklis Stavros
Diseases 2024, 12(9), 214; https://doi.org/10.3390/diseases12090214 - 13 Sep 2024
Viewed by 187
Abstract
Human papillomavirus (HPV) infections are significantly associated with multiple adverse reproductive outcomes such as miscarriages. Pregnant women are more susceptible to an HPV infection and its prevalence increases as pregnancy progresses. In this present review, we summarize the existing evidence indicating the potential [...] Read more.
Human papillomavirus (HPV) infections are significantly associated with multiple adverse reproductive outcomes such as miscarriages. Pregnant women are more susceptible to an HPV infection and its prevalence increases as pregnancy progresses. In this present review, we summarize the existing evidence indicating the potential impact of an HPV infection on the occurrence of recurrent pregnancy loss (RPL). Comprehensive research of the literature was performed in the Medline/PubMed and Scopus databases. A total of 185 articles were identified and 40 full-text articles were assessed. Four studies were eligible to be included in this literature review. To our knowledge, this is the first review aiming to summarize the current state of evidence regarding the possible association of HPV infections and RPL. Recurrent pregnancy loss constitutes a distressing reproductive event and scientific research has made significant efforts to determine the causes and mechanisms that could lead to RPL. It is still unclear whether the papillomavirus infection is associated with an increased risk for recurrent miscarriages. Research in the field revealed conflicting results and their deductions are limited by methodological limitations. Given the high prevalence of HPV infections and their potential role in the occurrence of adverse outcomes during pregnancy, further research is required to clarify the possibility of an HPV infection being a potential risk factor for recurrent miscarriages. Full article
Show Figures

Figure 1

Figure 1
<p>Flow diagram of the study selection process.</p>
Full article ">
13 pages, 652 KiB  
Article
Self-Screening for Cervical Cancer Offered through a Digital Platform in a Region of British Columbia with Lower Screening Rates
by Laurie W. Smith, Amy Booth, C. Sarai Racey, Brenda Smith, Ashwini Prabhakaran, Smritee Dabee, Quan Hong, Nazia Niazi and Gina S. Ogilvie
Curr. Oncol. 2024, 31(9), 5399-5411; https://doi.org/10.3390/curroncol31090399 - 13 Sep 2024
Viewed by 245
Abstract
Cervical cancer is highly preventable through vaccination, early detection, and treatment, yet is the fourth most common cancer globally. HPV testing is superior to cytology for the detection of cervical pre-cancer, and jurisdictions around the world are implementing HPV primary screening, which offers [...] Read more.
Cervical cancer is highly preventable through vaccination, early detection, and treatment, yet is the fourth most common cancer globally. HPV testing is superior to cytology for the detection of cervical pre-cancer, and jurisdictions around the world are implementing HPV primary screening, which offers the opportunity for self-screening, an important self-care intervention. Digital health solutions are also increasingly important components of self-care. In this study, we assessed the acceptability and completion of self-screening for cervical cancer offered through a digital platform within a low screening uptake region of British Columbia. The primary objective of this study was to evaluate the acceptability of self-screening for cervical cancer offered through a digital platform as measured by return rates of self-screening kits. Patients due or overdue for cervix screening were invited to participate. Eligible participants registered online to receive a self-screening kit, which included a device for vaginal self-screening, instructions, and a return envelope, sent to their home. After self-screening using the vaginal device, HPV testing was conducted. HPV-negative participants were returned to routine screening, and HPV-positive participants were recommended for cytology or colposcopy. Attendance rates at follow-up were evaluated. Participants were invited to complete an acceptability survey. From April 2019 to December 2023, 283 participants were sent kits, with 207 kits returned for a completion rate of 73%. Of valid samples (n = 202), 15 were HPV positive, and 93% attended follow-up care. Most respondents found the CervixCheck website easy to use, informative, and secure and were satisfied with receiving their results online. CervixCheck had a high completion rate among participants who were sent a self-screening kit. High compliance with recommended follow-up and high acceptability of self-screening for cervical cancer was observed. Most participants indicated they would self-screen again in the future. Innovative approaches to cervical screening, including self-screening and the use of digital health interventions, are ways to enhance equity and improve uptake of cervical screening. Full article
Show Figures

Figure 1

Figure 1
<p>Participation in CervixCheck. Any participants who withdrew from this study are not included in this analysis.</p>
Full article ">
8 pages, 242 KiB  
Communication
High-Risk HPV Detection in Paraffin-Embedded Tissue from Cervical Lesions
by Micaela Almeida, Vitor Caeiro, Diana Costa, Lara Silva, Cíntia Sousa, Paula Pestana, Sofia Campelos, João Vale, Ana Cristina Ramalhinho, José Fonseca-Moutinho and Luiza Breitenfeld
Pharmaceuticals 2024, 17(9), 1201; https://doi.org/10.3390/ph17091201 - 12 Sep 2024
Viewed by 333
Abstract
Background: Human papillomavirus (HPV), a leading cause of cervical cancer, is present in most cases of the disease and ranks as the fourth most common cancer in women globally. Among the HPV types, fourteen (HPV 16/18/31/33/35/39/45/51/52/56/58/59/66/68) are recognized as high-risk (hrHPV), each with [...] Read more.
Background: Human papillomavirus (HPV), a leading cause of cervical cancer, is present in most cases of the disease and ranks as the fourth most common cancer in women globally. Among the HPV types, fourteen (HPV 16/18/31/33/35/39/45/51/52/56/58/59/66/68) are recognized as high-risk (hrHPV), each with varying levels of oncogenic potential. Detecting and genotyping these hrHPV types in cervical lesions is crucial, requiring the development of new diagnostic methods. Methods: This study focuses on a retrospective analysis conducted on 44 women from the Cova da Beira Local Health Unit. We used the Anyplex™ II hrHPV Detection kit for hrHPV genotyping from paraffin-embedded cervical tissue samples. Results: hrHPV types were identified in 38 out of the 44 women. Genotyping revealed HPV-16 (55.3%), HPV-18/39/56/58/59 (5.3%), HPV-31 (21.1%), HPV-35 (7.9%), HPV-51/66 (2.6%), and HPV-52 (10.5%). Conclusions: This study demonstrates that the Anyplex™ II hrHPV Detection kit, originally designed for cervical cancer screening, is also effective for hrHPV genotyping in histological analyses. This methodology offers a simpler and more cost-effective approach for cervical cancer risk stratification. Its implementation in clinical practice could enhance the detection of hrHPV in cervical lesions, thereby contributing to more precise diagnoses and potentially more informed treatment strategies. Full article
(This article belongs to the Section Biopharmaceuticals)
17 pages, 1932 KiB  
Review
Lactoferrin: A Promising Therapeutic Molecule against Human Papillomavirus
by Merve Kaplan, Merve Baktıroğlu, Arda Erkan Kalkan, Ahmet Alperen Canbolat, Mauro Lombardo, António Raposo, José Luiz de Brito Alves, Anna Maria Witkowska and Sercan Karav
Nutrients 2024, 16(18), 3073; https://doi.org/10.3390/nu16183073 - 12 Sep 2024
Viewed by 597
Abstract
Lactoferrin is a multifunctional glycoprotein naturally found in mammalian secretions, predominantly in colostrum and milk. As a key component of dairy foods, lactoferrin enhances viral protection and boosts human health, owing to its fundamental properties including antiviral, anti-inflammatory, and immune-modulatory effects. Importantly, the [...] Read more.
Lactoferrin is a multifunctional glycoprotein naturally found in mammalian secretions, predominantly in colostrum and milk. As a key component of dairy foods, lactoferrin enhances viral protection and boosts human health, owing to its fundamental properties including antiviral, anti-inflammatory, and immune-modulatory effects. Importantly, the antiviral effect of lactoferrin has been shown against a range of viruses causing serious infections and threatening human health. One of the viruses that lactoferrin exerts significant antiviral effects on is the human papillomavirus (HPV), which is the most prevalent transmitted infection affecting a myriad of people around the world. Lactoferrin has a high potential to inhibit HPV via different mechanisms, including direct binding to viral envelope proteins or their cell receptors, thereby hindering viral entry and immune stimulation by triggering the release of some immune-related molecules through the body, such as lymphocytes. Along with HPV, lactoferrin also can inhibit a range of viruses including coronaviruses and hepatitis viruses in the same manner. Here, we overview the current knowledge of lactoferrin and its effects on HPV and other viral infections. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Potential antiviral effects of lactoferrin (PDB 1BLF) on papillomavirus. Lactoferrin can inhibit viral infection in its early stages by suppressing viral entry and/or inhibiting viral replication in further stages. It can directly attach to viral glycans found on their membranes and inhibit their binding to cell surface receptors (1a). It can also inhibit viral entry by binding to HSPGs, which are found on the cell membrane or free in the ECM, that are responsible for the viral entry mechanism (1b). It can bind to its receptors on the cell membrane and trigger some interferons that can prevent viral replication (2a) [<a href="#B6-nutrients-16-03073" class="html-bibr">6</a>,<a href="#B8-nutrients-16-03073" class="html-bibr">8</a>,<a href="#B18-nutrients-16-03073" class="html-bibr">18</a>] (Created with <a href="http://BioRender.com" target="_blank">BioRender.com</a>).</p>
Full article ">Figure 2
<p>HPV entry through host cells. HPV (type 16) attaches to laminin, free heparan sulfates in the ECM, or membrane (1,2), and the virus changed conformationally via exposing additional amino acids of the L2 N terminus. Then, the virion binds to integrin, which promotes intracellular signaling and further conformational changes (3). Following this, endocytosis of HPV16 takes place through the cytosol (4,5), lysozyme (6), and ER (7) to reach the nucleus [<a href="#B79-nutrients-16-03073" class="html-bibr">79</a>,<a href="#B80-nutrients-16-03073" class="html-bibr">80</a>,<a href="#B81-nutrients-16-03073" class="html-bibr">81</a>] (Created with <a href="http://BioRender.com" target="_blank">BioRender.com</a>).</p>
Full article ">Figure 3
<p>HPV infection and development of cervical cancer. HPV enters the basal cells via micro-abrasions in the cervical layer (1). Through further infection, the viral genome is replicated and progeny virions are formed to initiate a new infection which has a high risk to progress lesions (2,3). Untreated lesions are associated with early gene disruption (E2) and upregulation (E6–E7), which stimulates oncogene expression and invasive cancer development (4) [<a href="#B77-nutrients-16-03073" class="html-bibr">77</a>]. (Created with <a href="http://BioRender.com" target="_blank">BioRender.com</a>).</p>
Full article ">
9 pages, 243 KiB  
Article
Relationship between the Presence of Human Papillomavirus in the Female Urethra and Recurrent Urinary Tract Infections
by Cristina Mena-Ruiz, Julius Jan Szczesnieski, Magaly Márquez-Sánchez, Bárbara-Yolanda Padilla-Fernández, Javier Flores-Fraile and María-Fernanda Lorenzo-Gómez
J. Clin. Med. 2024, 13(17), 5329; https://doi.org/10.3390/jcm13175329 - 9 Sep 2024
Viewed by 494
Abstract
Introduction: Recurrent urinary tract infections (rUTIs) are highly prevalent health issues among women, significantly impacting their quality of life. Urethral pain or urethritis can arise from infectious or non-infectious origins. The presence of Human Papillomavirus (HPV) in the urogenital tract has been associated [...] Read more.
Introduction: Recurrent urinary tract infections (rUTIs) are highly prevalent health issues among women, significantly impacting their quality of life. Urethral pain or urethritis can arise from infectious or non-infectious origins. The presence of Human Papillomavirus (HPV) in the urogenital tract has been associated with high-risk sexual behaviors, but its presence in the female urethra without such behaviors has not been thoroughly investigated. Objectives: The study aims to determine the presence of HPV in the urethra of women with recurrent urinary tract infections (rUTIs) and concomitant urethral syndrome and to compare the clinical and microbiological characteristics of women with and without urethral HPV, specifically focusing on those without high-risk sexual behaviors. Methods: This prospective multicenter study included 138 women over 18 years old with rUTIs and concomitant urethral pain syndrome. High-risk sexual behaviors, sexually transmitted infections, and vaginitis were set as exclusion criteria. Participants were divided into two groups: NHPV (n = 72) with no urethral HPV and HPV (n = 66) with urethral HPV presence. Variables analyzed included age, body mass index (BMI), follow-up duration, comorbidities, treatments, toxic habits, surgical history, main symptoms, urine sediment findings, and cultures from urine and vaginal exudate. HPV genotyping was also performed. Descriptive statistics were used, along with Student’s t-test, Chi-square, Fisher’s exact test, ANOVA, and multivariate cluster analysis. Results: The NHPV group was older on average (48.75 years) compared to the HPV group (39.09 years). The HPV group had a longer follow-up period (2634 days vs. 1975 days in NHPV). Urinary incontinence was significantly more common in NHPV (63.89%) compared to HPV (18.18%) (p = 0.001). HPV-positive women had a higher prevalence of verrucous lesions in the vaginal introitus (64% vs. 8% in NHPV). Additionally, the HPV group showed higher rates of pyuria (27.27%), vaginal Candida albicans (36.26%), and positive urine cultures for Escherichia coli (47.83%), Enterococcus faecalis (36.36%), and Klebsiella pneumoniae (21.74%). No significant differences were observed between the groups concerning BMI, smoking habits, diabetes, or the main symptom at consultation. The most common HPV genotypes identified were G35, G42, and G66 (each 27%). Multivariate analysis revealed that sensitivity to nitrofurantoin was the most significant variable in the HPV group (importance of 0.96), followed by fosfomycin (0.79), trimethoprim (0.79), and amoxicillin (0.71). Conclusions: HPV was present in the urethra of 47.8% of women with rUTIs and concomitant urethral syndrome who did not exhibit high-risk sexual behaviors. These women were younger and had a longer duration of symptoms compared to those without urethral HPV. The identification of Enterococcus faecalis, Escherichia coli, and Klebsiella pneumoniae was more common in the HPV group. The sensitivity of bacteria to nitrofurantoin and fosfomycin is crucial for the clinical management of these patients. The presence of urethral HPV should be considered in the evaluation and treatment of women with rUTIs and urethral syndrome. Full article
(This article belongs to the Section Nephrology & Urology)
13 pages, 2330 KiB  
Article
Subgroup Analysis of TLR2, -3, -4 and -8 in Relation to the Severity of Clinical Manifestations of Cervical HPV Infection
by Alexander Dushkin, Maxim Afanasiev, Stanislav Afanasiev, Tatiana Grishacheva, Elena Biryukova, Irina Dushkina and Alexander Karaulov
Int. J. Mol. Sci. 2024, 25(17), 9719; https://doi.org/10.3390/ijms25179719 - 8 Sep 2024
Viewed by 422
Abstract
We present the findings of assessing the expression levels of extracellular TLR2 and TLR4 and intracellular TLR3 and TLR8 correlating with the severity of clinical manifestations of HPV infection. A total of 199 women took part in a single-center prospective comparative research study [...] Read more.
We present the findings of assessing the expression levels of extracellular TLR2 and TLR4 and intracellular TLR3 and TLR8 correlating with the severity of clinical manifestations of HPV infection. A total of 199 women took part in a single-center prospective comparative research study on TLR2, TLR3, TLR4 and TLR8 expression in HPV-related cervical lesions. TLRs’ mRNA expression was analyzed using real-time reverse transcription polymerase chain reaction (RT-PCR). Our results indicate the potential significance of TLR3, TLR4 and TLR8 in responding to HPV infection and its progression to SILs and CC, highlighting the importance of HPV polyinfection in relation to TLR4 and TLR8. Full article
Show Figures

Figure 1

Figure 1
<p>Comparison of TLRs in Group 1, Group 2 and Group 3. Note: RU—relative units; TLR—Toll-like receptor.</p>
Full article ">Figure 2
<p>Comparison of TLRs in subgroups of Group 2. Note: HPV—human papillomavirus; SIL—squamous intraepithelial lesion; RU—relative units; TLR—Toll-like receptor.</p>
Full article ">Figure 3
<p>Comparison of TLR3 in subgroups (HPV<sup>+(mono)</sup>/SIL<sup>−</sup> and HPV<sup>+(poly)</sup>/SIL<sup>−</sup>) of Group 2. Note: HPV—human papillomavirus; SIL—squamous intraepithelial lesion; RU—relative units; TLR—Toll-like receptor. * Group 1 vs. subgroup HPV<sup>+(mono)</sup>/SIL<sup>−</sup> vs. Group 3. ** Group 1 vs. subgroup HPV<sup>+(mono)</sup>/SIL<sup>−</sup> vs. subgroup HPV<sup>+(poly)</sup>/SIL vs. Group 3.</p>
Full article ">Figure 4
<p>Comparison of TLRs in Group 2 (LSIL) and Group 2 (HSIL). Note: HPV—human papillomavirus; HSIL—high-grade squamous intraepithelial lesion; LSIL—low-grade squamous intraepithelial lesion; RU—relative units; TLR—Toll-like receptor.</p>
Full article ">Figure 5
<p>Study design; HPV—human papillomavirus; HPV<sup>+(mono)</sup>—one HPV was detected; HPV<sup>+(poly)</sup>—more than one HPV was detected; HPV<sup>−</sup>—no HPV detected; HSIL—high-grade squamous intraepithelial lesion; ICC—invasive cervical cancer; LSIL—low-grade squamous intraepithelial lesion.</p>
Full article ">
25 pages, 1233 KiB  
Article
Human Papillomavirus Genotypes Distribution in High-Grade Cervical Lesions and Invasive Cervical Carcinoma in Women Living in Mauritania: Implications for Cervical Cancer Prevention and HPV Prophylactic Vaccination
by Mariem Salma Abdoudaim, Mohamed Val Mohamed Abdellahi, Nacer Dine Mohamed Baba, Ralph-Sydney Mboumba Bouassa, Mohamed Lemine Cheikh Brahim Ahmed and Laurent Bélec
Diagnostics 2024, 14(17), 1986; https://doi.org/10.3390/diagnostics14171986 - 8 Sep 2024
Viewed by 458
Abstract
Cervical cancer related to high-risk human papillomavirus (HR-HPV) is the second female cancer in Mauritania (Northwest Sahelian Africa). We assessed the distribution of HPV genotypes in Mauritanian women with high-grade cervical intraepithelial neoplasia (CIN2/3) or invasive cervical cancer (ICC). A prospective study was [...] Read more.
Cervical cancer related to high-risk human papillomavirus (HR-HPV) is the second female cancer in Mauritania (Northwest Sahelian Africa). We assessed the distribution of HPV genotypes in Mauritanian women with high-grade cervical intraepithelial neoplasia (CIN2/3) or invasive cervical cancer (ICC). A prospective study was conducted in the Centre Hospitalier National, Nouakchott, Mauritania, to collect cervical biopsies among women suspected of CIN2/3 or cancer. HPV DNA detection and genotyping were carried out from formalin-fixed, paraffin-embedded biopsies using multiplex PCR (Human Papillomavirus Genotyping Real-Time PCR Kit, Bioperfectus Technologies Co., Taizhou, China). Fifty biopsies were included from women (mean age: 56.7 years) suffering from CIN2/3 (28.0%) and ICC (72.0%) which corresponded to 32 (64.0%) squamous cell carcinomas (SCC) and 4 (8.0%) adenocarcinomas (ADC). HPV DNA detection was successful in 47 (94.0%) samples. The most prevalent HR-HPV genotypes were HPV-45 (40.4%), HPV-16 (38.3%), HPV-39 and HPV-52 (23.4%), HPV-33 (17.0%), HPV-18 (14.9%), HPV-35 (4.2%), and HPV-56 (2.1%). The majority (93.6%) of HPV-positive biopsies contained at least one HPV type covered by the 9-valent Gardasil-9® vaccine, and 40.9% were infected by multiple vaccine HPV genotypes. To eradicate cervical cancer in Mauritania, prophylactic HPV vaccination must be combined with primary molecular screening of cervical HR-HPV infection. Full article
(This article belongs to the Section Diagnostic Microbiology and Infectious Disease)
Show Figures

Figure 1

Figure 1
<p>Geographical map of Mauritania. Mauritania, officially the Islamic Republic of Mauritania, is a sovereign country in northwest Africa. It is bordered by the Atlantic Ocean to the West, western Sahara to the north and the northwest, Algeria to the northeast, Mali to the east and the southeast, and Senegal to the southwest. Mauritania is the 11th largest country in Africa, and 90% of its territory is situated in the Sahara Desert. Most of its population of 4.73 million inhabitants live in the temperate south of the country, with roughly one-third concentrated in the capital and largest city, Nouakchott, located on the Atlantic coast. All study participants were included in the Centre Hospitalier National in Nouakchott.</p>
Full article ">Figure 2
<p>Distribution of HPV types by histology. The samples were classified as high-grade cervical intraepithelial neoplasia (CIN2/3) or invasive cervical cancer, including adenocarcinoma (ADC) or squamous cell carcinoma (SCC). Nota bene: According to the manufacturer’s instructions and in accordance with the HPV classification nomenclature provided by the International Agency for Research on Cancer, the BMRT HPV Genotyping Real-Time PCR Kit distinguishes 21 HPV genotypes, including 14 genotypes (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68), 3 LR-HPV types (HPV-6, -11, and -81), and 4 genotypes classified as possibly oncogenic (HPV-26, -53, -73, and -82).</p>
Full article ">Figure 3
<p>Distribution of HPV genotypes according to their inclusion in the 9-valent Gardasil-9<sup>®</sup> vaccine: Percentage of low-risk (LR), high-risk (HR), and possibly carcinogenic HPV genotypes in 47 cervical samples positive for HPV DNA by molecular biology according to their possible prevention by Gardasil-9<sup>®</sup> vaccine among adult women living in Mauritania. Nota bene: The 9-valent Gardasil-9<sup>®</sup> vaccine (Merck &amp; Co. Inc., Rahway, NJ, USA) targets the seven HR-HPV genotypes predominantly isolated in cervical cancer (HPV-16, -18, -31, -33, -45, -52, and -58) and two LR-HPV (HPV-6 and HPV-11).</p>
Full article ">Figure 4
<p>Percentage of low-risk (LR), high-risk (HR), and possibly carcinogenic HPV genotypes in 47 cervical biopsies samples from adult women living in Mauritania, positive for HPV DNA not targeted by the 9-valent Gardasil-9<sup>®</sup> vaccine by using the BMRT HPV Genotyping Real-Time PCR Kit. Nota bene: The 9-valent Gardasil-9<sup>®</sup> vaccine (Merck &amp; Co. Inc., Rahway, NJ, USA) targets the seven HR-HPV genotypes predominantly isolated in cervical cancer (HPV-16, -18, -31, -33, -45, -52, and -58) and two LR-HPV (HPV-6 and HPV-11).</p>
Full article ">
9 pages, 2663 KiB  
Case Report
Case Report of Two Independent Moroccan Families with Syndromic Epidermodysplasia Verruciformis and STK4 Deficiency
by Assiya El Kettani, Hind Ouair, Farida Marnissi, Jalila El Bakkouri, Rémi Chevalier, Lazaro Lorenzo, Halima Kholaiq, Vivien Béziat, Emmanuelle Jouanguy, Jean-Laurent Casanova and Ahmed Aziz Bousfiha
Viruses 2024, 16(9), 1415; https://doi.org/10.3390/v16091415 - 5 Sep 2024
Viewed by 369
Abstract
Epidermodysplasia verruciformis (EV) is a rare genodermatosis caused by β-human papillomaviruses (HPV) in immunodeficient patients. EV is characterized by flat warts and pityriasis-like lesions and might be isolated or syndromic, associated with some other infectious manifestations. We report here three patients from two [...] Read more.
Epidermodysplasia verruciformis (EV) is a rare genodermatosis caused by β-human papillomaviruses (HPV) in immunodeficient patients. EV is characterized by flat warts and pityriasis-like lesions and might be isolated or syndromic, associated with some other infectious manifestations. We report here three patients from two independent families, with syndromic EV for both of them. By whole exome sequencing, we found that the patients carry new homozygous variants in STK4, both leading to a premature stop codon. STK4 deficiency causes a combined immunodeficiency characterized by a broad infectious susceptibility to bacteria, viruses, and fungi. Auto-immune manifestations were also reported. Deep immunophenotyping revealed multiple cytopenia in the three affected patients, in particular deep CD4+ T cells deficiency. We report here the fourth and the fifth cases of the syndromic EV due to STK4 deficiency. Full article
(This article belongs to the Special Issue Human and Animal Papillomavirus: Infections, Genetics, and Vaccines)
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>). Pictures of the lesions on the face and the back of P1. (<b>B</b>). Histological study of Punch skin biopsy showed hyperkeratosis and parakeratosis, mild acanthosis, and the presence of koilocytes, keratinocytes with pale-stained cytoplasm in the upper epidermis associated with high levels of intranuclear viral replication. The cytoplasm of the affected cells stains pale blue which is pathognomonic of epidermodysplasia verruciformis lesions without any sign of malignancy (arrows).</p>
Full article ">Figure 2
<p>(<b>A</b>). Pictures of the lesions on the face and the hand of P3. (<b>B</b>). Histological study of Punch skin biopsy showed hyperkeratosis and parakeratosis, mild acanthosis, and the presence of koilocytes, keratinocytes with pale-stained cytoplasm in the upper epidermis associated with high levels of intranuclear viral replication. The cytoplasm of the affected cells stains pale blue, which is pathognomonic of epidermodysplasia verruciformis lesions without any sign of malignancy (arrows).</p>
Full article ">Figure 3
<p>Pedigrees and familial segregation determined by Sanger sequencing of <span class="html-italic">STK4</span> variants in family 1 (<b>panel A</b>) and family 2 (<b>panel B</b>).</p>
Full article ">Figure 4
<p>CyTOF analysis on peripheral blood. (<b>A</b>). Proportion of total and subsets of NK cells, of total T cells, total T cells, γδ T cells, iNKT and MAIT cells. (<b>B</b>). Proportion of total and naïve, central memory, effector memory and EMRA CD4<sup>+</sup> T cells, T-regulatory, recent thymic emigrant (RTE) T cells and of total and naïve, central memory, effector memory and EMRA CD8<sup>+</sup> T cell subsets. (<b>C</b>). Proportion of total and memory, transitional, Age-associated B cells (ABC), plasmablasts, and switched B cell subsets. Age-matched healthy donors (black), patients (red). *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ns, not significant <span class="html-italic">p</span> ≥ 0.05.</p>
Full article ">
15 pages, 2102 KiB  
Article
Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity
by Kahren van Eer, Tsira Dzebisasjvili, Renske D. M. Steenbergen and Audrey J. King
Viruses 2024, 16(9), 1381; https://doi.org/10.3390/v16091381 - 29 Aug 2024
Viewed by 317
Abstract
HPV16 is occasionally detected in vaccinated women who received the bivalent HPV16/18 vaccine, usually at low viral loads. This study explored potential differences in HPV16 variants between vaccinated and unvaccinated women. HPV16-postive viral loads were detected in 1.9% (17/875) and 13% (162/760) of [...] Read more.
HPV16 is occasionally detected in vaccinated women who received the bivalent HPV16/18 vaccine, usually at low viral loads. This study explored potential differences in HPV16 variants between vaccinated and unvaccinated women. HPV16-postive viral loads were detected in 1.9% (17/875) and 13% (162/760) of vaccinated and unvaccinated women, respectively, showcasing the vaccine’s high efficacy. The L1, E6, and URR regions of HPV16 were sequenced from genital swabs from 16 vaccinated and 25 unvaccinated women in the HAVANA (HPV Among Vaccinated And Non-vaccinated Adolescents) study. The majority of HPV16 variants from vaccinated and unvaccinated women clustered similarly with sub-lineages A1 and A2. Additionally, a separate cluster within lineage A was found, with the variants sharing the L1-located SNP A753G (synonymous) and the URR-located SNP T340C, which did not occur in the other variants. Furthermore, four variants from vaccinated women had relatively long branches, but were not characterized by specific SNPs. The frequency of G712A in the URR was the only SNP observed to be marginally higher among vaccinated women than unvaccinated women. Non-synonymous SNPs T266A in the FG-loop of L1 and L83V in E6 were common among variants from vaccinated and unvaccinated women, but present in similar frequencies. In conclusion, the detection of HPV16 in vaccinated (and unvaccinated) women seemed to be the result of random circulation within this study population. Full article
(This article belongs to the Section Human Virology and Viral Diseases)
Show Figures

Figure 1

Figure 1
<p>Population characteristics, HPV16 prevalence and HPV16 viral load, with (<b>A</b>) an overview of the inclusion numbers in the HAVANA study and the HPV16 prevalence among vaccinated and unvaccinated women; and (<b>B</b>) HPV16 viral load measurements among vaccinated (left/white) and unvaccinated (right/green) women.</p>
Full article ">Figure 2
<p>L1–URR–E6 sequence coverage and load per sample. L1–URR–E6 sequence coverage (%) is shown on the Y-axis and the log10 of the HPV16 viral load (copies/cell) on the X-axis. Samples are grouped into Unvaccinated-Amplicon (circle, dark-grey), Unvaccinated-Shotgun (square, light-grey), Vaccinated-Amplicon (diamond, dark-green), Vaccinated-Shotgun (triangle, light-green).</p>
Full article ">Figure 3
<p>Maximum likelihood tree of the L1–URR–E6 consensus sequences from vaccinated women (green solid squares) and unvaccinated women (grey open squares). Reference sequences belonging to lineages A (violet), B (light purple), C (orange) and D (grey-green) are, respectively, indicated by ‘A1 to A4’, ‘B1 to B4’, ‘C1 to C4’ and ‘D1 to D4’. The long branches belong to S19, S27, S28 and S21, which are all from vaccinated women. The separate cluster is made up of three variants from unvaccinated women (S6, S34, S36) and one variant from vaccinated women (S24).</p>
Full article ">Figure 4
<p>The number of Single Nucleotide Polymorphisms (SNPs) found per HPV16 variant across the L1 (left panel), URR (middle panel) and E6 (right panel) regions in unvaccinated women (grey circles) and vaccinated women (green squares). Sequences were compared with reference K02718.1, from sub-lineage A1.</p>
Full article ">Figure 5
<p>Overview of the position and type of SNP found on each sequence from vaccinated (green squares) and unvaccinated women (black squares) compared to reference sequence K02718.1. Sample names are given on the <span class="html-italic">y</span>-axis and position of the SNPs on the <span class="html-italic">x</span>-axis. Variants from samples highlighted in blue were found to make up the separate cluster in lineage A. Two SNPs on the <span class="html-italic">x</span>-axis, also highlighted in blue, were only found in variants from this separate cluster. The variants from samples highlighted in orange have relatively long branches. Rows which are blocked by diagonal grey stripes represent variants for which no SNPs were found in a specific region.</p>
Full article ">
19 pages, 1383 KiB  
Article
Applying a Participatory Action Research Approach to Engage an Australian Culturally and Linguistically Diverse Community around Human Papillomavirus Vaccination: Lessons Learned
by Kathleen Prokopovich, Annette Braunack-Mayer, Jackie Street, Biljana Stanoevska, Leissa Pitts and Lyn Phillipson
Vaccines 2024, 12(9), 978; https://doi.org/10.3390/vaccines12090978 - 28 Aug 2024
Viewed by 313
Abstract
Globally, migrant and culturally and linguistically diverse (CALD) communities are known to have inequitable access to HPV vaccination. One participatory research approach used to engage CALD communities around vaccination is participatory action research (PAR), but we know little about the use of PAR [...] Read more.
Globally, migrant and culturally and linguistically diverse (CALD) communities are known to have inequitable access to HPV vaccination. One participatory research approach used to engage CALD communities around vaccination is participatory action research (PAR), but we know little about the use of PAR to engage priority migrant and CALD communities around school and HPV vaccination. To address this gap, we partnered with our local Multicultural Health Service to understand how the largest CALD group in our region of New South Wales, Australia, engages with their local school and HPV vaccination program. Through a long-standing PAR relationship, we used a participatory research method (World Café) approach to explore the level of awareness and engagement a multi-generational community member had concerning HPV vaccination. We acted by sharing a co-designed information website to answer the community’s questions about HPV vaccination. We then evaluated these engagements with surveys, focus groups and online analytic platforms. Last, we reflected with project partners and health service stakeholders on the overall project outcomes and shared our learnings. In our discussion, we shared our lessons learned and contributed to a wider conversation about the benefits, challenges, and practicalities of using PAR to engage a priority CALD community around HPV vaccination. Full article
(This article belongs to the Special Issue Promoting HPV Vaccination in Diverse Populations)
Show Figures

Figure 1

Figure 1
<p>Participatory action research (PAR) phases applied in this case study.</p>
Full article ">Scheme 1
<p>Sample table papers from the Cafés.</p>
Full article ">Scheme 2
<p>Sample images of approved website pages (available for viewing at: <a href="https://hpvvaccinationinterculturalcommunications.home.blog" target="_blank">https://hpvvaccinationinterculturalcommunications.home.blog</a> (accessed on 26 Aug 2024)).</p>
Full article ">
14 pages, 227 KiB  
Article
Attitudes toward Adolescent HPV Vaccination after the COVID-19 Pandemic: A National Survey of Mothers
by Gary Glauberman, Erica Liebermann, Melanie L. Kornides, Masako Matsunaga, Eunjung Lim, Gregory Zimet and Holly B. Fontenot
Vaccines 2024, 12(9), 976; https://doi.org/10.3390/vaccines12090976 - 28 Aug 2024
Viewed by 340
Abstract
In the United States, vaccination rates for many routinely recommended vaccines have recovered to pre-pandemic levels, yet human papillomavirus (HPV) vaccination rates still lag pre-pandemic levels. This study sought to uncover the potential effects of the pandemic on attitudes about the HPV vaccine, [...] Read more.
In the United States, vaccination rates for many routinely recommended vaccines have recovered to pre-pandemic levels, yet human papillomavirus (HPV) vaccination rates still lag pre-pandemic levels. This study sought to uncover the potential effects of the pandemic on attitudes about the HPV vaccine, and factors associated with changes in attitudes. We conducted a national survey (n = 3968) of U.S. mothers with children aged 9–17 years. Outcome variables measured changes in attitude toward the HPV vaccine following the pandemic. Two logistic regression models identified predictors of (1) those who did not have attitude changes (always negative vs. always positive), and (2) those who reported attitude changes (change to negative vs. change to positive). Attitudes toward the HPV vaccine remained unchanged in 78.9% of participants (58.1% positive, 20.8% negative). Of the 21.1% reporting changed attitudes, 9.6% changed to positive and 11.5% to negative. Those reporting changing to a negative attitude had a greater odds of reporting conservative political views, and being unsure/undecided about vaccinating their child against HPV compared to those who reported changing to a positive attitude. Targeted strategies are needed to address erosion in confidence in the HPV vaccine and other vaccines resulting from mis- and disinformation associated with the COVID-19 pandemic and future pandemics. Full article
(This article belongs to the Special Issue Advancing the Science on Vaccine Hesitancy to Inform Interventions)
13 pages, 1324 KiB  
Article
Analysis of Expression and Regulation of AKR1C2 in HPV-Positive and -Negative Oropharyngeal Squamous Cell Carcinoma
by Maria Ziogas, Oliver Siefer, Nora Wuerdemann, Harini Balaji, Elena Gross, Uta Drebber, Jens Peter Klussmann and Christian U. Huebbers
Cancers 2024, 16(17), 2976; https://doi.org/10.3390/cancers16172976 - 27 Aug 2024
Viewed by 369
Abstract
Head and Neck Squamous Cell Carcinoma (HNSCC), particularly Oropharyngeal Squamous Cell Carcinoma (OPSCC), is a major global health challenge due to its increasing incidence and high mortality rate. This study investigates the role of aldo-keto reductase 1C2 (AKR1C2) in OPSCC, focusing on its [...] Read more.
Head and Neck Squamous Cell Carcinoma (HNSCC), particularly Oropharyngeal Squamous Cell Carcinoma (OPSCC), is a major global health challenge due to its increasing incidence and high mortality rate. This study investigates the role of aldo-keto reductase 1C2 (AKR1C2) in OPSCC, focusing on its expression, correlation with Human Papillomavirus (HPV) status, oxidative stress status, and clinical outcomes, with an emphasis on sex-specific differences. We analyzed AKR1C2 expression using immunohistochemistry in formalin-fixed, paraffin-embedded tissue samples from 51 OPSCC patients. Additionally, we performed RT-qPCR in cultured HPV16-E6*I and HPV16-E6 overexpressing HEK293 cell lines (p53WT). Statistical analyses were performed to assess the correlation between AKR1C2 expression and patient data. Our results indicate a significant association between increased AKR1C2 expression and higher AJCC classification (p = 0.009) as well as positive HPV status (p = 0.008). Prognostic implications of AKR1C2 varied by sex, whereby female patients with high AKR1C2 expression had better overall survival, whereas male patients exhibited poorer outcomes. Additionally, AKR1C2 expression was linked to HPV status, suggesting a potential HPV-specific regulatory mechanism. These findings underscore the complex interplay among AKR1C2, HPV, and patient sex, highlighting the need for personalized treatment strategies for OPSCC. Targeted inhibition of AKR1C2, considering sex-specific differences, may enhance therapeutic outcomes. Future research should investigate these mechanisms to enhance treatment efficacy. Full article
(This article belongs to the Collection Molecular Signaling Pathways and Networks in Cancer)
Show Figures

Figure 1

Figure 1
<p>Representative immunohistochemical staining against AKR1C2 in non-tumorous (small rectangular images) and tumor tissue samples (<b>A</b>–<b>D</b>). AKR1C2<sup>LOW</sup> indicates lower and AKR1C2<sup>HIGH</sup> indicates higher expression of AKR1C2 compared to the adjacent non-tumorous epithelium. (<b>A</b>,<b>C</b>) HPV-negative (HPV−) OPSCC, (<b>B</b>,<b>D</b>) HPV-positive (HPV+) OPSCC. V = x200.</p>
Full article ">Figure 2
<p>Univariate survival analysis for AKR1C2 expression status with low vs. high protein expression in tumor compared to adjacent non-tumorous epithelium. <span class="html-italic">p</span> value was derived by log-rank/Mantel–Cox test. Analyses of HPV status (<b>B</b>), AKR1C2 expression combined with sex, and combinations of AKR1C2 expression and HPV status in women (<b>J</b>) and men (<b>K</b>) proved to be significant.</p>
Full article ">Figure 3
<p>mRNA expression of AKR1C1, AKR1C2, and AKR1C3 in HEK293 cells overexpressing HPV16-E6 or HPV16-E6*I. Hypoxanthine Phosphoribosyltransferase (HPRT) was used for normalization of mRNA levels. (****) <span class="html-italic">p</span> &lt; 0.00001.</p>
Full article ">
17 pages, 676 KiB  
Article
Experiences and Perceptions of Cervical Cancer Screening Using Self-Sampling among Under-Screened Women in Flanders
by Charlotte Buelens, Margot Stabel, Alice Wildiers, Lieve Peremans, Guido Van Hal, Lotje Van Doorsselaere, Annouk Lievens, Alex Vorsters, Severien Van Keer and Veronique Verhoeven
Healthcare 2024, 12(17), 1704; https://doi.org/10.3390/healthcare12171704 - 26 Aug 2024
Viewed by 621
Abstract
Primary Human Papillomavirus (HPV) screening on samples collected by women themselves has proven to be an effective strategy for cervical cancer screening (CCS) and may increase participation rates in women who do not partake (regularly) in screening. The aim of this study is [...] Read more.
Primary Human Papillomavirus (HPV) screening on samples collected by women themselves has proven to be an effective strategy for cervical cancer screening (CCS) and may increase participation rates in women who do not partake (regularly) in screening. The aim of this study is to investigate reasons for non-participation and perceptions of CCS using self-sampling methods among under-screened women in Flanders. Individual interviews with 15 underscreened women aged 30–64 years were conducted. During the interviews, participants were given the opportunity to try out a urine and vaginal self-sampling kit. Thematic analysis was based on Ajzen’s model of the Theory of Planned Behavior. The results showed that 14 out of 15 participants were more likely to participate in CCS if they had the option to self-sample. One of the main findings was a lack of knowledge on different aspects of cervical cancer. Most women had a positive attitude toward cancer screening and primary prevention such as HPV vaccination. Subjective norms were influenced by healthcare professionals, peers, and organized government initiatives. Informational, organizational, contextual, and emotional factors were mentioned as barriers as well as facilitators for participation. Additionally, high self-efficacy was considered to make self-sampling more convenient. All women showed the intention to use at least one method of self-sampling. We can conclude that women who do not participate in CCS would be more motivated to participate using self-sampling methods. Adequate education and guidance should be provided. Full article
(This article belongs to the Section Women's Health Care)
Show Figures

Figure 1

Figure 1
<p>Ajzen’s model of the Theory of Planned Behavior with adaptations. Figure adapted from [<a href="#B22-healthcare-12-01704" class="html-bibr">22</a>].</p>
Full article ">
Back to TopTop